Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is listed today as Eikon Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2025 | $351 M | No. 4 | $250 million to $1 billion | equity, options | SEC | |
| May 2023 | $141 M | No. 3 | $50 to $250 million | equity | SEC | |
| Dec 2021 | $518 M | No. 2 | $250 million to $1 billion | equity | SEC | |
| May 2021 | $103 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Eikon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2025
That is all the official record says: Eikon Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Eikon Therapeutics, Inc. are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Column Group IV-A, LP | Fund or asset manager | not stated | not stated | Held Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Column Group IV GP, LP | Fund or asset manager | not stated | not stated | Held Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Column Group Opportunity III GP, LP | Fund or asset manager | not stated | not stated | Held Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Column Group Opportunity III, LP | Fund or asset manager | not stated | not stated | Held Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Management IV, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Opportunity Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital Opportunity Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital VI-A, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Foresite Capital VI-A Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Lux Co-Invest Opportunities II, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026) | SEC Form 3 |
| Lux Total Opportunities, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026) | SEC Form 3 |
| Lux Venture Partners V, LLC | Venture capital | not stated | not stated | Held Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026) | SEC Form 3 |
| Lux Ventures V, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026) | SEC Form 3 |
| TCG Opportunity III GP, LLC | Other | not stated | not stated | Held Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 43 investors.
Largest shareholders today
Institutions holding Eikon Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$44 M10.19%
- BlackRock, Inc.$39 M8.99%
- Foresite Capital Management IV, LLC$16 M3.59%
- Merck & Co., Inc.$13 M3.08%
- T. Rowe Price Investment Management, Inc.$13 M3.02%
- Foresite Capital Management V, LLC$11 M2.43%
- Capital World Investors$9 M2.17%
- Price T Rowe Associates Inc /MD/$9 M2.05%
- Alliancebernstein L.P.$8 M1.94%
- Vanguard Capital Management LLC$8 M1.87%
- EcoR1 Capital, LLC$7 M1.58%
- Geode Capital Management, LLC$6 M1.39%
- Regents Of The University Of California$5 M1.17%
- State Street Corp$5 M1.12%
- Baker Bros. Advisors LP$4 M1.03%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Roger M. Perlmutter | Executive officer | Feb 2025 |
| Alfred M. Bowie | Executive officer | Jun 2023 |
| Ashish M. Kheterpal | Executive officer | Jun 2023 |
| Barbara M. Howes | Executive officer | Jun 2023 |
| Benjamin M. Thorner | Executive officer | Jun 2023 |
| Dan M. Anderson | Executive officer | Jun 2023 |
| Roy M. Banes | Executive officer | Jun 2023 |
| Russ M. Berman | Executive officer | Jun 2023 |
| Leon Chen | Executive officer | May 2021 |
| Roger M Perlmutter | Executive officer | May 2021 |
| Dror M. Berman | Director | Feb 2025 |
| James M. Tananbaum | Director | Feb 2025 |
| Joshua M. Wolfe | Director | Feb 2025 |
| Kenneth M. Frazier | Director | Feb 2025 |
| Leon M. Chen | Director | Feb 2025 |
| Robbie M. Huffines | Director | Feb 2025 |
| Robin M. Washington | Director | Feb 2025 |
| Roger M. Perlmutter | Director | Feb 2025 |
| Josh M. Wolfe | Director | Jun 2023 |
| Adam M. Goulburn | Director | Jan 2022 |
| Adam Goulburn | Director | May 2021 |
| Dror Berman | Director | May 2021 |
| James M Tananbaum | Director | May 2021 |
| Leon Chen | Director | May 2021 |
| Roger M Perlmutter | Director | May 2021 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.